1. FDA Critical Path Initiatives: Opportunities for Generic Drug Development
2. CFR. ‐ Code of Federal Regulations Title 21 Volume 5 Revised as of April 1 2019. Available fromhttps://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=320.23[Accessed 02/23/2021]
3. United States Food and Drug Administration. 21CFR320.23. Available from:https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=320.23[Accessed 02/23/2020]
4. FDA.Product‐Specific Guidances for Generic Drug Development. Available from:https://www.fda.gov/drugs/guidances‐drugs/product‐specific‐guidances‐generic‐drug‐development[Accessed 02/23/2021]
5. A new paradigm for topical generic drug products: Impact on therapeutic access